Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 3
1977 18
1978 28
1979 21
1980 6
1981 1
1985 1
1986 2
1987 2
1988 2
1989 3
1990 2
1996 1
1999 2
2000 24
2001 62
2002 86
2003 144
2004 142
2005 142
2006 147
2007 166
2008 128
2009 256
2010 543
2011 716
2012 752
2013 743
2014 728
2015 723
2016 573
2017 578
2018 709
2019 316
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

6,956 results
Results by year
Filters applied: . Clear all
Page 1
Drug combination studies and their synergy quantification using the Chou-Talalay method.
Chou TC. Cancer Res 2010. PMID 20068163 Free article.
This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. ...The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations. ...
This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination stu …
Combination drug therapy for the treatment of status epilepticus.
Wang X, et al. Expert Rev Neurother 2015 - Review. PMID 26035623
In light of the diverse etiology and complex pathogenesis of SE, combination drug therapy for SE might be more conducive for the treatment of all patients because the combined use of drugs can produce synergistic effects via different mechanisms. This review summarizes combination drug therapies used for SE in animal experiments and clinical practice, the potential advantages of combination drug therapy and specific combination drug therapies using different antiepileptic drugs. ...
In light of the diverse etiology and complex pathogenesis of SE, combination drug therapy for SE might be more conducive for t …
Using combination therapy to thwart drug resistance.
Hill JA and Cowen LE. Future Microbiol 2015 - Review. PMID 26597425
Drug combination therapy is a promising strategy to extend the lifespan of our antimicrobials. Drug combinations used in treatment must be carefully selected to minimize the evolution of resistance, either by carefully determining drug pairs that hinder the acquisition of resistance mechanisms, or by screening for combinations that inhibit growth and show reduced vulnerability to resistance. Modeling of interactions between drugs has provided intriguing insights into strategies for combination therapy deployment. Ultimately, more rigorous clinical trials need to be performed to evaluate the laboratory and modeling results and advance treatment options....
Drug combination therapy is a promising strategy to extend the lifespan of our antimicrobials. Drug combinations used i
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ and Griffith DE. Microbiol Spectr 2017 - Review. PMID 28361737
Revised drug classifications include the use of linezolid and clofazimine as key second-line drugs and the option to use bedaquiline and delamanid to complete a five-drug regimen when needed due to poor medication tolerance or extensive resistance. Despite multiple drugs and long-duration treatment regimens, the outcomes for MDR and especially XDR-TB are much worse than for drug-susceptible disease. ...
Revised drug classifications include the use of linezolid and clofazimine as key second-line drugs and the option to use bedaquiline …
Pulmonary Arterial Hypertension: Combination Therapy in Practice.
Burks M, et al. Am J Cardiovasc Drugs 2018 - Review. PMID 29511993 Free PMC article.
Combination therapy is now regarded as the standard of care in pulmonary arterial hypertension (PAH) and is becoming widely used in clinical practice. ...Despite their differing modes of action, all of the currently available classes of PAH therapy induce systemic vasodilation. ...
Combination therapy is now regarded as the standard of care in pulmonary arterial hypertension (PAH) and is becoming widely used in c …
Network-based prediction of drug combinations.
Cheng F, et al. Nat Commun 2019. PMID 30867426 Free PMC article.
Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple complex diseases. ...This finding allows us to identify and validate antihypertensive combinations, offering a generic, powerful network methodology to identify efficacious combination therapies in drug development....
Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple c
The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL, et al. Drug Metab Dispos 2018 - Review. PMID 29695614
Several safe and highly effective direct-acting antiviral (DAA) drugs for chronic hepatitis C virus (HCV) have been developed and greatly increase the number of therapeutic options available to successfully treat HCV infection. However, because treatment regimens contain at least two drugs (e.g., elbasvir and grazoprevir, glecaprevir and pibrentasvir, or sofosbuvir with daclatasvir, simeprevir, ledipasvir, or velpatasvir) and up to five drugs (ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin), the potential for drug-drug interactions (DDIs) becomes an important consideration for HCV-infected individuals with comorbidities that require concomitant medications, such as human immunodeficiency virus/HCV coinfection or immunosuppression after liver transplantation. ...
Several safe and highly effective direct-acting antiviral (DAA) drugs for chronic hepatitis C virus (HCV) have been developed and greatly in …
Emerging therapies for acute myeloid leukemia.
Saygin C and Carraway HE. J Hematol Oncol 2017 - Review. PMID 28420416 Free PMC article.
The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors. ...
The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadeci …
Benefits and risks of rapid initiation of antiretroviral therapy.
Ford N, et al. AIDS 2018. PMID 29112073 Free PMC article.
BACKGROUND: Recent attention has focused on the question of how quickly antiretroviral therapy (ART) should be started once HIV diagnosis is confirmed. ...
BACKGROUND: Recent attention has focused on the question of how quickly antiretroviral therapy (ART) should be started once HIV diagn …
6,956 results
Jump to page
Feedback